Paper Details

  1. Home
  2. Paper Details

Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary Haemophilus influenzae Type b (Hib) Vaccination Series.

Author: BriereElizabeth C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Hiberix (Haemophilus b Conjugate Vaccine [Tetanus Toxoid Conjugate]) has been approved for use as a 3-dose infant primary vaccination series at ages 2, 4, and 6 months, providing another option for Hib vaccination in infants.
Paper Details　
Original Abstract of the Article :
On January 14, 2016, GlaxoSmithKline Biologicals (Research Triangle Park, North Carolina) received approval from the Food and Drug Administration (FDA) to expand use of Hiberix (Haemophilus b Conjugate Vaccine [Tetanus Toxoid Conjugate]) for a 3-dose infant primary vaccination series at ages 2, 4, a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.15585/mmwr.mm6516a3

データ提供：米国国立医学図書館（NLM）

FDA Approval of Hiberix for Infant Haemophilus influenzae Type b (Hib) Vaccination Series

This research ventures into the vital field of public health, focusing on the expansion of Hiberix, a Haemophilus influenzae type b (Hib) vaccine, for use in infants. This approval, like a refreshing desert spring providing much-needed hydration, signifies a significant step forward in protecting infants from this potentially life-threatening disease.

Expanding Vaccination Options

The study highlights the importance of expanding vaccination options for infants, providing parents with a wider range of choices for protecting their children. This expansion, much like a desert caravan offering diverse goods, aims to ensure that every infant has access to the best possible protection from Hib disease.

Safe and Effective Vaccination

The researchers emphasize the safety and efficacy of Hiberix for infants, reassuring parents that this vaccine offers a reliable and safe way to protect their children. This assurance, like a sturdy desert caravan offering a safe passage through treacherous terrain, provides parents with peace of mind.

Dr.Camel's Conclusion

This research marks a significant milestone in the fight against Hib disease, providing parents with a valuable tool for protecting their infants. It's a testament to the power of science and collaboration, much like the desert's ability to sustain life through its intricate ecosystem.
Date :
  1. Date Completed 2016-12-22
  2. Date Revised 2019-01-07
Further Info :

Pubmed ID

27124887

DOI: Digital Object Identifier

10.15585/mmwr.mm6516a3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.